Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Jiangsu Yuanben Biotechnology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution involves 1 distinct examiner and 1 distinct art unit. MOSHER, ERIC PARKER is the busiest examiner, with 1 pending office action. This single pending matter defines the current prosecution landscape for the entity within this technical field.
The 1 to 1 ratio between pending office actions and distinct examiners shows that the company's current prosecution is entirely concentrated under MOSHER, ERIC PARKER. As the busiest examiner, he is responsible for the only active matter in the Biotechnology & Pharmaceuticals area. The involvement of 1 distinct art unit indicates that the technical review is focused within a single specialized group. This centralized prosecution means that the company is currently interacting with only 1 examiner and 1 art unit. Practitioners should note that there is no spread of matters across multiple officials, as the 1 pending action represents the entirety of the company's active workload. This focused activity suggests a specific patent objective for the current period, with the 1 pending office action being the sole focus of the company's efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905207 | HER2 AFFIBODY RADIONUCLIDE MARKER COMPOSITION AND APPLICATION THEREOF | MOSHER, ERIC PARKER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905207 | HER2 AFFIBODY RADIONUCLIDE MARKER COMPOSITION AND APPLICATION THEREOF | MOSHER, ERIC PARKER | 1612 | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJiangsu Yuanben Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Parker Mosher has the most, with 1 of Jiangsu Yuanben Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.